Pharmaceutical sponsor
Minghui Pharmaceutical (Hangzhou) Ltd Clinical Trials
Studies where Minghui Pharmaceutical (Hangzhou) Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 13Thyroid Eye Disease, TED
Treatment of Chronic Thyroid Eye Disease With MHB018A
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
- Trial name
- NCT07622121
- Testing
- MHB018A injection
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease, TED
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.
- Trial name
- NCT07622108
- Testing
- MHB018A
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Cancer
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB046C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT06985355
- Testing
- MHB046C
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Malignant Solid Tumor
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB088C combined with MHB039A in patients with advanced malignant solid tumors.
- Trial name
- NCT07126665
- Testing
- MHB088C for Injection, MHB039A for Injection
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Malignant Solid Tumor
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07045454
- Testing
- MHB118C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Breast Cancer, Advanced Malignant Solid Tumor
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors.
- Trial name
- NCT07130383
- Testing
- MHB036C for Injection, MHB039A for Injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Vitiligo
A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo
This is a randomized, double-blind, multicenter, placebo-controlled clinical study intended to evaluate the efficacy, safety and population pharmacokinetic profiles of MH004 ointment in eligible participants with NSV.
- Trial name
- NCT07682506
- Testing
- MH004 1.0% Ointment
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Malignant Solid Tumor
A Study of MHB009C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB009C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07326488
- Testing
- MHB009C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Malignant Solid Tumor
A Study of MHB042C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192107
- Testing
- MHB042C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd